종양학용 RWE(Real World Evidence) 솔루션 시장 규모, 점유율, 동향 분석 보고서 : 구성요소별, 데이터 유형별, 암 유형별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Real World Evidence Solutions For Oncology Market Summary

The global real world evidence solutions for oncology market size was valued at USD 703.2 million in 2025 and is projected to grow from USD 761.8 million in 2026 to USD 1,437.1 million by 2033, at a CAGR of 9.5% from 2026 to 2033. North America dominated the market, accounting for the largest share of 43.1% in 2025. The market growth is primarily driven by the increasing global cancer burden, rising adoption of real-world data (RWD) and real-world evidence (RWE) in oncology drug development and regulatory decision-making, growing demand for value-based healthcare, and expanding use of RWE to support precision oncology, post-market surveillance, and reimbursement decisions.

Global Real World Evidence Solutions For Oncology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global real world evidence solutions for oncology market report on the basis of component, data type, cancer type, application, end use, and region:

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Services
• Data Sets
• Data Type Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Data
• Claims Data
• Pharmacy Data
• Patient-Generated Data
• Cancer Registry Data
• Genomic & Biomarker Data
• Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Hematologic Malignancies
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Development & Clinical Research
• Regulatory Decision Making
• Market Access & Reimbursement
• Post-Market Safety Monitoring
• Precision Oncology
• Comparative Effectiveness Research
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Healthcare Companies
  • Clinical research
  • Commercial (inclusive of marketing, etc.)
  • HEOR
  • Others (market access, etc.)
• Healthcare Payers
• Healthcare Providers
• Other
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Component Segment
    • 1.1.1.2. Data Type Segment
    • 1.1.1.3. Cancer Type Segment
    • 1.1.1.4. Application Segment
    • 1.1.1.5. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. List of Secondary Sources
  • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Demand for Cost-Effective Drug Development
    • 3.2.1.2. Increasing Adoption of Precision Oncology and Biomarker-Driven Therapies
    • 3.2.1.3. Rising Demand for Post-Market Surveillance and Long-Term Therapy Outcome Evaluation
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Data Privacy Concerns
    • 3.2.2.2. Lack of Standardized Data Formats and Interoperability Challenges Across Healthcare Systems
    • 3.2.2.3. Limited Availability of High-Quality, Structured Oncology Datasets
  • 3.2.3. Market Opportunities Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Economic landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Component Business Analysis

• 4.1. Segment Dashboard
• 4.2. Real World Evidence Solutions For Oncology Market: Component Movement Analysis
• 4.3. Services
  • 4.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 4.4. Data Sets
  • 4.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 5. Data Type Business Analysis

• 5.1. Segment Dashboard
• 5.2. Real World Evidence Solutions For Oncology Market: Data Type Movement Analysis
• 5.3. Clinical Data
  • 5.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.4. Claims Data
  • 5.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.5. Pharmacy Data
  • 5.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.6. Patient-Generated Data
  • 5.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.7. Cancer Registry Data
  • 5.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.8. Genomic & Biomarker Data
  • 5.8.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 6. Cancer Type Business Analysis

• 6.1. Segment Dashboard
• 6.2. Real World Evidence Solutions For Oncology Market: Cancer Type Movement Analysis
• 6.3. Breast Cancer
  • 6.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.4. Lung Cancer
  • 6.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.5. Colorectal Cancer
  • 6.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.6. Prostate Cancer
  • 6.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.7. Hematologic Malignancies
  • 6.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Segment Dashboard
• 7.2. Real World Evidence Solutions For Oncology Market: Application Movement Analysis
• 7.3. Drug Development & Clinical Research
  • 7.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.4. Regulatory Decision Making
  • 7.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.5. Market Access & Reimbursement
  • 7.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.6. Post-Market Safety Monitoring
  • 7.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.7. Precision Oncology
  • 7.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.8. Comparative Effectiveness Research
  • 7.8.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Segment Dashboard
• 8.2. Real World Evidence Solutions For Oncology Market: End Use Movement Analysis
• 8.3. Healthcare Companies
  • 8.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 8.3.2. Clinical research
    • 8.3.2.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 8.3.3. Commercial (inclusive of marketing, etc.)
    • 8.3.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 8.3.4. HEOR
    • 8.3.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 8.3.5. Others (market access, etc.)
    • 8.3.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.4. Healthcare Payers
  • 8.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.5. Healthcare Providers
  • 8.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.6. Other
  • 8.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Real World Evidence Solutions For Oncology Market Share By Region, 2025 & 2033
• 9.2. North America
  • 9.2.1. North America Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Competitive Scenario
    • 9.2.2.3. Regulatory Framework
    • 9.2.2.4. U.S. Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Competitive Scenario
    • 9.2.3.3. Regulatory Framework
    • 9.2.3.4. Canada Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Competitive Scenario
    • 9.2.4.3. Regulatory Framework
    • 9.2.4.4. Mexico Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. UK Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Germany Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. France Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Competitive Scenario
    • 9.3.5.3. Regulatory Framework
    • 9.3.5.4. Italy Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Competitive Scenario
    • 9.3.6.3. Regulatory Framework
    • 9.3.6.4. Spain Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Competitive Scenario
    • 9.3.7.3. Regulatory Framework
    • 9.3.7.4. Denmark Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Competitive Scenario
    • 9.3.8.3. Regulatory Framework
    • 9.3.8.4. Sweden Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Competitive Scenario
    • 9.3.9.3. Regulatory Framework
    • 9.3.9.4. Norway Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Japan Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. China Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. India Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Australia Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.4.6. Thailand
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Thailand Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.4.7. South Korea
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. South Korea Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Brazil Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Argentina Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
• 9.6. MEA
  • 9.6.1. MEA Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. South Africa Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Saudi Arabia Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Competitive Scenario
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. UAE Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Competitive Scenario
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Kuwait Real World Evidence Solutions For Oncology Market, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Company Market Share/ Position Analysis, 2025
• 10.3. Strategy Mapping
• 10.4. Company Profiles/Listing
  • 10.4.1. IQVIA
    • 10.4.1.1. Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Merative
    • 10.4.2.1. Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. PPD, Inc. (a subsidiary of Thermo Fisher Scientific Inc.)
    • 10.4.3.1. Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. Parexel International Corporation
    • 10.4.4.1. Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. ICON Plc
    • 10.4.5.1. Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. Oracle
    • 10.4.6.1. Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Syneos Health
    • 10.4.7.1. Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. Cegedim group
    • 10.4.8.1. Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. Optum, Inc. (a subsidiary of UnitedHealth Group)
    • 10.4.9.1. Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. SAS Institute Inc.
    • 10.4.10.1. Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic Initiatives
  • 10.4.11. Aetion, Inc. (acquired by Datavant)
    • 10.4.11.1. Overview
    • 10.4.11.2. Financial Performance
    • 10.4.11.3. Product Benchmarking
    • 10.4.11.4. Strategic Initiatives
  • 10.4.12. Flatiron Health
    • 10.4.12.1. Overview
    • 10.4.12.2. Financial Performance
    • 10.4.12.3. Product Benchmarking
    • 10.4.12.4. Strategic Initiatives
  • 10.4.13. Trinity Partners, LLC.
    • 10.4.13.1. Overview
    • 10.4.13.2. Financial Performance
    • 10.4.13.3. Product Benchmarking
    • 10.4.13.4. Strategic Initiatives